View in EDS HTML Full Text PDF Full Text

Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma.

Saved in:
Bibliographic Details
Title: Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma.
Authors: Chen, Wenming1 (AUTHOR) 13910107759@163.com, Fu, Chengcheng2 (AUTHOR) fuchengchengsz@163.com, Fang, Baijun3 (AUTHOR), Liang, Aibin4 (AUTHOR), Xia, Zhongjun5 (AUTHOR), He, Yanjuan6 (AUTHOR), Lu, Jin7 (AUTHOR), Liu, Hui8 (AUTHOR), Hou, Ming9 (AUTHOR), Cai, Zhen10 (AUTHOR), Yang, Wei11 (AUTHOR), Hao, Siguo12 (AUTHOR), Jiang, Songfu13 (AUTHOR), Jing, Hongmei14 (AUTHOR), Liu, Jing15 (AUTHOR), Du, Xin16 (AUTHOR), Fu, Rong17 (AUTHOR), Mei, Heng18 (AUTHOR), Zhu, Zunmin19 (AUTHOR), Yang, Yanli20 (AUTHOR)
Source: Experimental Hematology & Oncology. 9/30/2025, Vol. 14 Issue 1, p1-14. 14p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21623619
DOI:10.1186/s40164-025-00710-y